Use of Cyproterone Acetate (Cpa) in the Treatment of Acne, Hirsutism and Virilism

Hammerstein, J.; Meckies, J.; Leo-Rossberg, I; Moltz, L.; Zielske, F

doi:10.1016/b978-0-08-019682-4.50109-8

Cited by 29 publications

(45 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The goal of this approach was to obtain a regular menstrual cycle and to improve the clinical signs of hyperandrogenism (12)(13)(14). In some women with PCOS with hirsutism, OCs must be combined with high doses (12.5-100 mg/d) of cyproterone acetate (CPA) or with flutamide for better suppression of hair growth (15)(16)(17)(18). Because OCs may activate the coagulation system and their use may be associated with a deterioration of carbohydrate metabolism and lipid profile, at present the use of OCs in women with PCOS is still under scrutiny (19).…”

mentioning

confidence: 99%

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

Fruzzetti

Perini

Lazzarini

et al. 2010

Fertility and Sterility

View full text Add to dashboard Cite

mentioning

confidence: 99%

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

Fruzzetti

Perini

Lazzarini

et al. 2010

Fertility and Sterility

View full text Add to dashboard Cite

“…Several antiandrogenic drugs such as spironolactone, cyproterone acetate and flutamide have been used as a single drug or combined in the treatment of hirsutism 20,[29][30][31][32][33][34][35] . A long treatment period is always required to improve hirsutism and to prevent or to delay its relapse.…”

Section: Discussionmentioning

confidence: 99%

The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism

Lakryc

Motta

Soares

et al. 2003

Gynecological Endocrinology

View full text Add to dashboard Cite

Finasteride has been used frequently in the treatment of prostate hyperplasia, but this drug inhibits 5alpha-reductase and for this reason could be useful for the treatment of hirsutism. The aim of this study was to evaluate the clinical and hormonal effects of finasteride on hirsute women with idiopathic hirsutism or polycystic ovary syndrome. Twenty-four women were randomly divided into two groups: those given placebo and those given finasteride 5 mg/day. The treatment period was 6 months. All patients were evaluated before the beginning of treatment (baseline) and after 3 and 6 months of treatment using clinical examination through Ferriman-Gallwey score, blood pressure, cardiac frequency and body mass index. Also, we collected blood for hormonal determination of levels of prolactin, 17alpha-hydroxyprogesterone, follicle stimulating hormone, luteinizing hormone, total and free testosterone, dehydroepiandrosterone sulfate, androstenedione and dihydrotestosterone. Furthermore, all patients were asked about their concerns and satisfaction with the treatment. The results showed that the Ferriman-Gallwey score in the 6th month of finasteride treatment was significantly lower than at baseline and the 3rd month of this drug treatment. The dihydrotestosterone level in the finasteride group was also significantly reduced compared to that in the placebo group. The other hormones did not show any statistical difference during the study. All the patients treated with finasteride perceived a reduction in hirsutism after 6 months. In conclusion, our data suggest that finasteride may be effective for the treatment of the hirsute woman with idiopathic hirsutism or polycystic ovary syndrome.

show abstract

“…We suggest that 50 mg CA once a day for 10 days each menstrual cycle could be effective for virtually all the patients with severe hirsutism. Higher doses, as those proposed by Hammerstein et al (167) are clearly of no greater benefit and may 508 BIFFIGNANDI, MASSUCCHETTI, AND MOLINATTI Vol. 5,No.…”

Section: B Pharmacological Properties Of Antiandrogensmentioning

confidence: 94%

Female Hirsutism: Pathophysiological Considerations and Therapeutic Implications*

1984

View full text Add to dashboard Cite

Use of Cyproterone Acetate (Cpa) in the Treatment of Acne, Hirsutism and Virilism

Cited by 29 publications

References 4 publications

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism

Female Hirsutism: Pathophysiological Considerations and Therapeutic Implications*

Contact Info

Product

Resources

About